You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC

LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

  • Authors: Charles H. Yoon, PhD, MD, FACS; Inderjit Mehmi, MD; Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC
  • CME / ABIM MOC Released: 11/16/2023
  • Valid for credit through: 11/16/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 1.00 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 1.00 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, dermatologists, surgeons, pathologists, and other clinicians involved in the care of patients with metastatic melanoma.

The goal of this activity is for learners to better understand the role of the multidisciplinary team (MDT) in the optimal care of patients receiving LAG-3 inhibitor-containing regimens for metastatic melanoma.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • LAG-3 inhibitor-containing regimens used for the treatment of metastatic melanoma
  • Have greater competence related to
    • Determining patient eligibility for LAG-3 inhibitor-containing regimens in metastatic melanoma
    • Creating personalized care plans for patients with metastatic melanoma as part of the MDT
  • Demonstrate greater confidence in their ability to
    • Engage patients with metastatic melanoma in shared decision-making for treatment considerations


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Charles H. Yoon, PhD, MD, FACS

    Director of Surgery for Cutaneous Oncology and Melanoma
    Dana Farber Cancer Institute
    Director of Surgical Oncology
    Merkel Cell Carcinoma Center of Excellence
    Associate Surgeon
    Surgical Oncology
    Brigham and Women's Hospital
    Assistant Professor of Surgery
    Harvard Medical School
    Boston, Massachusetts

    Disclosures

    Charles H. Yoon, PhD, MD, FACS, has no relevant financial relationships.

  • Inderjit Mehmi, MD

    Medical Oncologist
    Hematology Oncology
    Cedars-Sinai The Angeles Clinic and Research Institute
    Los Angeles, California

    Disclosures

    Inderjit Mehmi, MD, has the following relevant financial relationships:
    Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Immunocore
    Owns stock (publicly traded) in: Delcath; Ideaya; Immunocore; In8Bio

  • Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC

    Melanoma/Cutaneous Oncology and Phase 1 Research
    New York University Langone Perlmutter Cancer Center
    New York, New York

    Disclosures

    Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC, has no relevant financial relationships.

Editors

  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

  • Jason Luis Quiñones, PhD

    Associate Medical Writer, Medscape, LLC

    Disclosures

    Jason Luis Quiñones, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

SITC Course Director

  • Dirk Schadendorf, MD

    Director & Chair
    Department of Dermatology
    Director
    Comprehensive Cancer Center (Westdeutsches Tumorzentrum)
    University Hospital Essen & Research Alliance Ruhr
    Founding Director
    Research Center One Health
    University Duisburg-Essen
    Essen, Germany

    Disclosures

    Dirk Schadendorf, MD, has the following relevant financial relationships:
    Consultant or advisor for: 4SC; Agenus; Astra Zeneca; BioAlta; Bristol Myers Squibb Company; Curevac; Daiichi Sankyo, Inc.; Erasca; Haystack; Hexal; Immatics; Immunocore; InFlarX; Merck-Serono; Merck Sharp & Dohme; Neracare; Novartis; NovoGenix; PamGene; Philogen; Pierre Fabre; Pfizer, Inc.; Regeneron; Replimune; Roche; Sanofi; Seagen, Inc.; Sun Pharma; UltimoVacs
    Speaker or member of speakers bureau for: Bristol Myers Squibb Company; Merck-Serono; Merck Sharp & Dohme; Neracare
    Research funding from: Amgen, Inc., Bristol Myers Squibb Company; Merck Sharp & Dohme; Novartis; Roche

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Developed through a partnership between Medscape and SITC.

Medscape

Interprofessional Continuing Education

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer (SITC). Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as noncertified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's “CME in Support of MOC” program in Section 3 of the Royal College's MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

Authors: Charles H. Yoon, PhD, MD, FACS; Inderjit Mehmi, MD; Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BCFaculty and Disclosures

CME / ABIM MOC Released: 11/16/2023

Valid for credit through: 11/16/2024, 11:59 PM EST

processing....

Contents of This Activity

To start this activity, please assess your clinical knowledge by completing the brief survey at the bottom. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

The Cutting Edge: Surgical Considerations for Metastatic Melanoma

Dr Charles Yoon discusses how surgeons aid in the optimal diagnosis of metastatic melanoma.
Charles H. Yoon, MD, PhD, FACS

Incorporating LAG-3 Into the Treatment Armamentarium

Dr Inderjit Mehmi delves into when LAG-3 inhibitor-containing regimens should be considered for patients with metastatic melanoma.
Inderjit Mehmi, MD

Engaging Patients in Shared Decision-Making

Kathy Madden explores how to engage patients in shared decision-making.
Kathy Madden, RN, MSN, FNP-BC, AOCNP, APHN-BC
 

Learning Feedback Questions

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print